There are several ongoing phase 2/3 trials in China, testing the effect of disitamab vedotin in different subsets of breast cancer: two studies in HER-2-positive metastatic breast cancer (NCT05331326; NCT03500380); three studies in HER-2-low metastatic breast cancer (NCT04400695; NCT05904964; NCT06105008); and finally, two studies in the neoadjuvant setting of HER-2-positive breast cancer (NCT05134519; NCT05726175) (see Table 7). Here, ERBB2 is linked to breast carcinoma.